Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Stock Short Interest Declines 59.8%

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a significant decrease in short interest in September. As of September 15th, there was short interest totaling 48,204 shares, a decrease of 59.8% from the August 31st total of 119,854 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 259,918 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Trading of Enlivex Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP lifted its holdings in shares of Enlivex Therapeutics by 1,428.5% in the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock worth $87,000 after buying an additional 147,334 shares in the last quarter. WINTON GROUP Ltd bought a new position in shares of Enlivex Therapeutics during the 2nd quarter valued at about $55,000. Finally, Bank of America Corp DE lifted its holdings in shares of Enlivex Therapeutics by 53.2% in the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after acquiring an additional 45,303 shares during the last quarter. 1.02% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ENLV. Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Zacks Research upgraded Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $247.50.

Enlivex Therapeutics Stock Performance

Shares of Enlivex Therapeutics stock traded down $0.07 on Monday, reaching $0.53. 461,635 shares of the company’s stock were exchanged, compared to its average volume of 133,405. The company has a market capitalization of $9.27 million, a P/E ratio of -0.06 and a beta of 1.42. Enlivex Therapeutics has a 52 week low of $0.52 and a 52 week high of $27.15. The firm’s 50-day moving average is $1.77 and its two-hundred day moving average is $8.17.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore immune-system balance, or immune homeostasis, in patients experiencing severe or dysregulated inflammation. The company focuses on conditions in which an excessive or impaired immune response may contribute to organ damage and other serious complications.

Its lead product candidate, Allocetra-OTS, is an off-the-shelf cell therapy made from healthy apoptotic cells.